Article

Imaging the biogenesis of individual HIV-1 virions in live cells

Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10065, USA.
Nature (Impact Factor: 42.35). 08/2008; 454(7201):236-40. DOI: 10.1038/nature06998
Source: PubMed

ABSTRACT Observations of individual virions in live cells have led to the characterization of their attachment, entry and intracellular transport. However, the assembly of individual virions has never been observed in real time. Insights into this process have come primarily from biochemical analyses of populations of virions or from microscopic studies of fixed infected cells. Thus, some assembly properties, such as kinetics and location, are either unknown or controversial. Here we describe quantitatively the genesis of individual virions in real time, from initiation of assembly to budding and release. We studied fluorescently tagged derivatives of Gag, the major structural component of HIV-1-which is sufficient to drive the assembly of virus-like particles-with the use of fluorescence resonance energy transfer, fluorescence recovery after photobleaching and total-internal-reflection fluorescent microscopy in living cells. Virions appeared individually at the plasma membrane, their assembly rate accelerated as Gag protein accumulated in cells, and typically 5-6 min was required to complete the assembly of a single virion. These approaches allow a previously unobserved view of the genesis of individual virions and the determination of parameters of viral assembly that are inaccessible with conventional techniques.

Download full-text

Full-text

Available from: Nolwenn Jouvenet, Aug 26, 2015
0 Followers
 · 
135 Views
  • Source
    • "In subsequent sections we illustrate how different experimental systems have yielded complementary pieces of the HIV-1 assembly puzzle, while highlighting important questions that remain unanswered and concepts that could reconcile contrasting assembly models. Other topics related to HIV-1 assembly have been reviewed elsewhere and will only be mentioned here in passing, including gRNA trafficking and packaging (reviewed in Kuzembayeva et al., 2014; Lu et al., 2011), HIV-1 budding and release (reviewed in Votteler and Sundquist, 2013), HIV-1 maturation (reviewed in Sundquist and Krausslich, 2012), and the subcellular localization of HIV-1 assembly (reviewed in Jouvenet et al., 2008; Klein et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: During the late stage of the viral life cycle, HIV-1 Gag assembles into a spherical immature capsid, and undergoes budding, release, and maturation. Here we review events involved in immature capsid assembly from the perspective of five different approaches used to study this process: mutational analysis, structural studies, assembly of purified recombinant Gag, assembly of newly-translated Gag in a cell-free system, and studies in cells using biochemical and imaging techniques. We summarize key findings obtained using each approach, point out where there is consensus, and highlight unanswered questions. Particular emphasis is placed on reconciling data suggesting that Gag assembles by two different paths, depending on the assembly environment. Specifically, in assembly systems that lack cellular proteins, high concentrations of Gag can spontaneously assemble using purified nucleic acid as a scaffold. However, in the more complex intracellular environment, barriers that limit self-assembly are present in the form of cellular proteins, organelles, host defenses, and the absence of free nucleic acid. To overcome these barriers and promote efficient immature capsid formation in an unfavorable environment, Gag appears to utilize an energy-dependent, host-catalyzed, pathway of assembly intermediates in cells. Overall, we show how data obtained using a variety of techniques has led to our current understanding of HIV assembly.
    Virus Research 11/2014; 193. DOI:10.1016/j.virusres.2014.07.001 · 2.83 Impact Factor
  • Source
    • "During maturation, HIV also packages its reverse transcriptase and integrase enzymes (encoded by pol gene), which are required for infection (Seibert et al., 1995) (Fig. 2C). Complete assembly takes about 5–6 min (Jouvenet et al., 2008, 2009). The genomes of plant viruses are either monopartite or multipartite (segmented) (Rao, 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Genome encapsidation is an essential step in the life cycle of viruses. Viruses either use some of the most powerful ATP-dependent motors to compel the genetic material into the preformed capsid or make use of the positively charged proteins to bind and condense the negatively charged genome in an energy-independent manner. While the former is a hallmark of large DNA viruses, the latter is commonly seen in small DNA and RNA viruses. Discoveries of many complex giant viruses such as mimivirus, megavirus, pandoravirus, etc., belonging to the nucleo-cytoplasmic large DNA virus (NCLDV) superfamily have changed the perception of genome packaging in viruses. From what little we have understood so far, it seems that the genome packaging mechanism in NCLDVs has nothing in common with other well-characterized viral packaging systems such as the portal-terminase system or the energy-independent system. Recent findings suggest that in giant viruses, the genome segregation and packaging processes are more intricately coupled than those of other viral systems. Interestingly, giant viral packaging systems also seem to possess features that are analogous to bacterial and archaeal chromosome segregation. Although there is a lot of diversity in terms of host range, type of genome, and genome size among viruses, they all seem to use three major types of independent innovations to accomplish genome encapsidation. Here, we have made an attempt to comprehensively review all the known viral genome packaging systems, including the one that is operative in giant viruses, by proposing a simple and expanded classification system that divides the viral packaging systems into three large groups (types I–III) on the basis of the mechanism employed and the relatedness of the major packaging proteins. Known variants within each group have been further classified into subgroups to reflect their unique adaptations.
    Virology 10/2014; 466. DOI:10.1016/j.virol.2014.06.022 · 3.28 Impact Factor
  • Source
    • "It has been known for decades that retroviruses can tolerate the incorporation of heterologous proteins (Jones et al., 1990; Weldon et al., 1990). Lentiviral particles (LPs) have been engineered to carry foreign proteins for the purpose of visualizing the intracellular behavior of the virus during infection (McDonald et al., 2002; Jouvenet et al., 2008) and altering the viral integration profile (Bushman, 1994; Goulaouic and Chow, 1996; Bushman and Miller, 1997), as well as for ferrying antiviral (Okui et al., 2000; Ao et al., 2008) and antitumor (Link et al., 2006; Miyauchi et al., 2012) protein therapeutics . As the delicate structural composition of HIV-1-derived lentiviral particles is easily disturbed by an inappropriate load of nonviral proteins, leading to suboptimal vector yields and/or reduced transduction capability, various strategies for transducing heterologous protein cargo have been scrutinized. "
    [Show abstract] [Hide abstract]
    ABSTRACT: eLife digest Altering the genetic code of a living organism to produce certain desirable outcomes is the goal of genetic engineering. The field builds on a long history of human attempts to alter genetics, from selective breeding of crops and livestock to genetically modified organisms and gene therapies. Researchers routinely use gene editing to create ‘knock-out’ mice in which a particular gene is turned off: the researchers can learn more about the function of this gene by watching what happens when it is absent. As gene editing techniques have grown more sophisticated, they have become an increasingly promising tool for treating diseases that are caused by gene mutations. The aim of this work is to replace faulty genes with genes that work properly. However, it has been difficult to adapt genetic engineering techniques so that they can be used safely in humans. Scientists have created customized enzymes called nucleases that can remove specific genes, but it has been a challenge to get these nucleases into cells in the first place. A virus can be used to deliver the genes that encode these nucleases into the DNA of a cell, but this approach can lead to the production of too many nucleases and to the removal of more genes than intended. Now Cai et al. have developed a ‘hit-and-run’ method for getting the nucleases into cells and making them active only for a short period of time. This method involves using a virus to deliver two different nucleases to a cell. Once inside the cell, the viruses released the nucleases, which were able to remove up to one-quarter of their gene targets, with relatively few errors, in the time that they were active. Next, Cai et al. added gene patches—new genes to replace those removed by the nucleases—to the viruses. This ‘cut and patch’ strategy was successful in up to 8% of the treated cells. The results also suggest that this approach is safer than other gene-editing techniques. DOI: http://dx.doi.org/10.7554/eLife.01911.002
    eLife Sciences 04/2014; 3:e01911. DOI:10.7554/eLife.01911 · 8.52 Impact Factor
Show more